G<sub>2</sub>/M cell cycle arrest and apoptosis induced by COH‑203 in human promyelocytic leukemia HL‑60 cells

Lin,Jihong; Zhang,Lei; Wang,Zhiwei; Guan,Qi; Bao,Kai; Wu,Lan

doi:10.3892/ol.2021.13076

December-2021 Volume 22 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2021 Volume 22 Issue 6

Full Size Image

Article Open Access

G₂/M cell cycle arrest and apoptosis induced by COH‑203 in human promyelocytic leukemia HL‑60 cells

Authors:
- Jihong Lin
- Lei Zhang
- Zhiwei Wang
- Qi Guan
- Kai Bao
- Lan Wu
View Affiliations / Copyright

Affiliations: Department of Geratology, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China, Key Laboratory of Structure‑Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China

Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 815
|
Published online on: September 28, 2021

https://doi.org/10.3892/ol.2021.13076
Expand metrics +

Abstract

The combretastatin A‑4/oltipraz hybrid (COH), 5‑(3‑amino‑4‑methoxyphenyl)‑4‑(3,4,5‑trimethoxyphenyl)‑3H‑1,2‑dithiole‑3‑one (COH‑203) is one of the COH compounds synthesized by our previous study, which has been reported to affect a number of cancer cell lines, such as SGC‑7901, KB, HT‑1080, HepG2, SMMC‑7721 and BEL‑7402. The sensitivity of human acute leukemia cell lines to COH‑203, and the mechanism underlying its anti‑proliferative effects remain unknown, which was investigated in the present study. In the present study, it was demonstrated that COH‑203 had notable time‑ and dose‑dependent antiproliferative effects on the human acute promyelocytic leukemia HL‑60 cell line. Furthermore, COH‑203 treatment resulted in cell cycle arrest at G₂/M phase in a dose‑dependent manner, and subsequently induced apoptosis. Western blot analysis revealed that upregulation of cyclin B was associated with G₂/M arrest. In addition, treatment with COH‑203 resulted in downregulated expression of Bcl‑2. This result revealed that COH‑203‑induced apoptosis in HL‑60 cells may occur via the mitochondrial pathway in a caspase‑dependent manner.

View Figures

View References

1	Kadia TM, Ravandi F, O'Brien S, Cortes J and Kantarjian HM: Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 15:139–151. 2015. View Article : Google Scholar : PubMed/NCBI
2	Al-Hussaini M and DiPersio JF: Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol. 7:439–464. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ng CH and Chng WJ: Recent advances in acute promyelocytic leukaemia. F1000Res. 6:12732017. View Article : Google Scholar : PubMed/NCBI
4	Coombs CC, Tavakkoli M and Tallman MS: Acute promyelocytic leukemia: Where did we start, where are we now, and the future. Blood Cancer J. 5:e3042015. View Article : Google Scholar : PubMed/NCBI
5	McCulloch D, Brown C and Iland H: Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: Current perspectives. Onco Targets Ther. 10:1585–1601. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhou GB, Zhang J, Wang ZY, Chen SJ and Chen Z: Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci. 362:959–971. 2007. View Article : Google Scholar : PubMed/NCBI
7	Zhou J and Giannakakou P: Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 5:65–71. 2005. View Article : Google Scholar : PubMed/NCBI
8	Chen SM, Meng LH and Ding J: New microtubule-inhibiting anticancer agents. Expert Opin Investig Drugs. 19:329–343. 2010. View Article : Google Scholar : PubMed/NCBI
9	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
10	Wang Z, Qi H, Shen Q, Lu G, Li M, Bao K, Wu Y and Zhang W: 4,5-Diaryl-3H-1,2-dithiole-3-thiones and related compounds as combretastatin A-4/oltipraz hybrids: Synthesis, molecular modelling and evaluation as antiproliferative agents and inhibitors of tubulin. Eur J Med Chem. 122:520–529. 2016. View Article : Google Scholar : PubMed/NCBI
11	Qi H, Zuo DY, Bai ZS, Xu JW, Li ZQ, Shen QR, Wang ZW, Zhang WG and Wu YL: COH-203, a novel microtubule inhibitor, exhibits potent anti-tumor activity via p53-dependent senescence in hepatocellular carcinoma. Biochem Biophys Res Commun. 455:262–268. 2014. View Article : Google Scholar : PubMed/NCBI
12	Pistritto G, Trisciuoglio D, Ceci C, Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 4:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
13	Greene LM, Campiani G, Lawler M, Williams DC and Zisterer DM: BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol. 73:419–430. 2008. View Article : Google Scholar : PubMed/NCBI
14	Haring SJ, Mason AC, Binz SK and Wold MS: Cellular functions of human RPA1. Multiple roles of domains in replication, repair, and checkpoints. J Biol Chem. 283:19095–19111. 2008. View Article : Google Scholar : PubMed/NCBI
15	Schafer KA: The cell cycle: A review. Vet Pathol. 35:461–478. 1998. View Article : Google Scholar : PubMed/NCBI
16	Ling YH, El-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol. 49:832–841. 1996.PubMed/NCBI
17	Knudsen KE, Knudsen ES, Wang JY and Subramani S: p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe. Proc Natl Acad Sci USA. 93:8278–8283. 1996. View Article : Google Scholar : PubMed/NCBI
18	Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH and Teng CM: CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther. 7:350–360. 2008. View Article : Google Scholar : PubMed/NCBI
19	Peng X, Yu Z, Liang N, Chi X, Li X, Jiang M, Fang J, Cui H, Lai W, Zhou Y and Zhou S: The mitochondrial and death receptor pathways involved in the thymocytes apoptosis induced by aflatoxin B1. Oncotarget. 7:12222–12234. 2016. View Article : Google Scholar : PubMed/NCBI
20	Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
21	Du X, Fu XF, Yao K, Lan ZW, Xu H, Cui QH and Yang E: Bcl-2 delays cell cycle through mitochondrial ATP and ROS. Cell Cycle. 16:707–713. 2017. View Article : Google Scholar : PubMed/NCBI
22	Gupta S: Molecular signaling in death receptor and mitochondrial pathways of apoptosis. Int J Oncol. 22:15–20. 2003.PubMed/NCBI
23	Hatok J and Racay P: Bcl-2 family proteins: Master regulators of cell survival. Biomol Concepts. 7:259–270. 2016. View Article : Google Scholar : PubMed/NCBI
24	Gupta S, Kass GE, Szegezdi E and Joseph B: The mitochondrial death pathway: A promising therapeutic target in diseases. J Cell Mol Med. 13:1004–1033. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sun BB, Fu LN, Wang YQ, Gao QY, Xu J, Cao ZJ, Chen YX and Fang JY: Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. J Dig Dis. 15:491–500. 2014. View Article : Google Scholar : PubMed/NCBI
26	Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
27	Dou C, Han M, Zhang B, Sun L, Jin X and Li T: Chrysotoxene induces apoptosis of human hepatoblastoma HepG2 cells in vitro and in vivo via activation of the mitochondria-mediated apoptotic signaling pathway. Oncol Lett. 15:4611–4618. 2018.PubMed/NCBI
28	Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI

Journals